[144] Jazz Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Jazz Pharmaceuticals (JAZZ) has filed a Form 144 indicating that Chairman & CEO Bruce C. Cozadd intends to sell up to 9,000 common shares through Merrill Lynch on or about 1 Aug 2025. Based on the reference price in the filing, the sale is valued at approximately $1.10 million, equal to ~0.01% of the company’s 61.6 million shares outstanding.

The shares were acquired via equity-compensation grants made between December 2021 and February 2022. Over the past three months Cozadd has already sold 2,500 shares for gross proceeds of $276.6 k. The filer certifies under Rule 144 that he possesses no undisclosed material adverse information.

While such sales are common for liquidity or tax purposes, investors often view continued insider selling—especially by the CEO—as a potential signal of tempered confidence. Market watchers may track any additional Form 4 filings or 10b5-1 plan disclosures for context.

Positive

• None.

Negative

• CEO insider selling: Proposed sale of 9,000 shares (~$1.1 M) follows 2,500 shares sold in prior three months, potentially pressuring investor sentiment.
• No 10b5-1 plan cited: Absence of an explicit pre-arranged trading plan may heighten scrutiny around timing and intent of transactions.

Insights

Securities Analyst

TL;DR: Routine CEO sale of 9k JAZZ shares (~$1.1M); modest size, sentiment slightly cautious but not fundamentally material.

At ~0.01% of shares out, the proposed divestiture is immaterial to Jazz’s capital structure and unlikely to affect liquidity. However, combined with recent 2.5k-share sales, it could weigh on sentiment given Cozadd’s leadership role. No operational data or guidance changes accompany the filing, so fundamentals remain unchanged. I classify the impact as neutral; monitor follow-on insider activity for trend confirmation.

Corporate Governance Specialist

TL;DR: Consecutive insider disposals by CEO may flag governance-related perception risk despite compliance with Rule 144.

Insider selling is legal and expected for diversification, but transparency matters. Cozadd’s aggregate planned and recent sales total 11,500 shares (~$1.4 M). While still small, clustered transactions can prompt investor questions about strategic outlook. Lack of an explicitly disclosed 10b5-1 plan in the filing leaves room for speculation. I view the disclosure as modestly negative for near-term perception, though not a red flag on its own.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
common	Merrill Lynch 3075B Hansen Way 1st Floor Palo Alto CA 94304	9000	1096210.00	61632841	08/01/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
common	02/01/2022	Equity Compensation	Jazz Pharmaceuticals PLC			747	02/01/2022	Equity Compensation
Common	01/03/2022	Equity Compensation	Jazz Pharmaceuticals PLC			7818	01/03/2022	Equity Compensation
Common	12/01/2021	Equity Compensation	Jazz Pharmaceuticals PLC			435	12/01/2021	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Bruce C Cozadd FIFTH FLOOR, WATERLOO EXCHANGE WATERLOO ROAD dublin L2 D04 E5W7	Common	07/01/2025	1000	107630.00
Bruce C Cozadd Fifth Floor, Waterloo Exchange Waterloo Exchange Dublin L2 D04 E5W7	Common	06/03/2025	500	55000.00
Bruce C Cozadd Fifth Floor, Waterloo Exchange Waterloo DUBLIN L2 D04 E5W7	Common	06/02/2025	500	53950.00
Bruce C Cozadd FIFTH FLOOR, WATERLOO EXCHANGE WATERLOO ROAD Dublin L2 D04 E5W7	Common	05/02/2025	500	60000.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many Jazz Pharmaceuticals (JAZZ) shares are slated for sale?

The Form 144 covers up to 9,000 common shares.

What is the estimated value of the planned JAZZ share sale?

At the reference price in the filing, the sale is worth about $1.10 million.

Who is the insider selling JAZZ stock?

Chairman & CEO Bruce C. Cozadd is the selling shareholder.

When is the anticipated sale date for the shares?

The approximate sale date listed is 1 August 2025.

Have there been recent insider sales at Jazz Pharmaceuticals?

Yes. Cozadd sold 2,500 shares between May and July 2025 for gross proceeds of $276.6 k.

What percentage of outstanding shares does the planned sale represent?

Roughly 0.01% of the 61.6 million shares outstanding.